PROTACs
PROTAC (PROteolysis-TArgeting Chimera) is a heterobifunctional nanomolecule containing two different ligands, ligand for ubiquitin E3 and ligand for target protein. The two parts are connected by linker to form a "three-unit" polymer, target protein ligand-linker-E3 ligase ligand. Building blocks of PROTAC molecules include PROTAC Linker, Ligand for Target Protein for PROTAC, Ligand for E3 Ligase, E3 Ligase Ligand-Linker Conjugate, Target Protein Ligand-Linker Conjugate, etc.
PROTACs Isoform Specific Products
All Product Categories
-
PROTACs Related Products (1355)
Related Products (1355)
-
Antibodies (1)
-
PROTACs Isoform Comparison
-
Homo-BacPROTAC7 TFA
0 ImagesCat. No.: HY-153572AHomo-BacPROTAC7 TFA is a PROTAC protein degrader targeting ClpC1/ClpC2 with a Kd of 0.5-2.5 nM for both targets. Homo-BacPROTAC7 (TFA) acts as a bactericidal agent, induces killing of pathogenic mycobacteria, retains activity against dormant-like mycobacterial cells with reduced intracellular ATP levels, and shows elevated antibiotic potency relative to its parent monomer. Homo-BacPROTAC7 (TFA) can be used for the research of tuberculosis.
-
GNE-987 GSH linker-2
0 ImagesCat. No.: HY-138634Purity: 99.48%GNE-987 GSH linker-2 is a drug-linker conjugates for ADC. GNE-987 GSH linker-2 is a conjugation of PROTAC GNE-987 (HY-129937A) and ADC linker GSH linker-2 (HY-182740), and can be used to prepare antibody-drug conjugates (ADC) for BRD4 degradation. GNE-987 GSH linker-2 can be used for the research of cancer.
-
PROTAC BRD4 Degrader linker conjugate-3
0 ImagesPROTAC BRD4 Degrader linker conjugate-3 is a VHL-recruiting PROTAC that targets and degrades BRD4. It can be used in studies related to prostate cancer.
-
PROTAC MDM2 Degrader-1
0 ImagesPROTAC MDM2 Degrader-1 (Compound 15a) is a MDM2 PROTAC degrader. The structures of both Linker ends of PROTAC MDM2 Degrader-1 are MDM2 ligands. PROTAC MDM2 Degrader-1 can not only block the binding of p53-MDM2, but also degrade the target MDM2 protein by utilizing the function of the E3 ligase of MDM2 itself, thus exerting an anti-tumor effect.
-
QC-182
0 ImagesQC-182 is a p300/CBP PROTAC degrader with a DC50 of 93 nM against p300. QC-182 induces ubiquitination and proteasomal degradation of p300 and CBP in a CRBN-dependent manner. QC-182 induces Apoptosis. QC-182 exhibits anticancer activity against liver cancer cells. QC-182 can be used for the research of hepatocellular carcinoma.
-
PROTAC CBP/P300 Degrader-3
0 ImagesSynonyms: Thalidomide-NH-CBP/p300 ligand 2
-
PROTAC K-Ras Degrader-2
0 ImagesCat. No.: HY-164365CAS No.: 3043670-74-9PROTAC K-Ras degrader-2 (compound 48) is a KRAS G12V PROTAC degrader with an IC50 of 20-200 nM for KRAS G12V/RAF1. PROTAC K-Ras degrader-2 degrades SW620 KRAS G12V with a DC50 of 1-10 nM. PROTAC K-Ras degrader-2 inhibits cell growth of SW620 3D cell with an IC50 of ≤10 nM. PROTAC K-Ras degrader-2 can be used for the study of colorectal cancer (CRC).
-
APH02174 hemiformic
0 ImagesCat. No.: HY-174455AAPH02174 hemiformic is a highly selective and orally active IRAK4 PROTAC degrader with the DC50 of 4.01 nM in THP-1 cells. APH02174 hemiformic blocks inflammatory signals by inhibiting IL-6 release. APH02174 hemiformic can be used for research on inflammatory conditions such as psoriasis vulgaris and rheumatoid arthritis.
-
YJ9069
0 ImagesCat. No.: HY-168556YJ9069 is a CDK12/CDK13 PROTAC degrader. YJ9069 induces proteasome-dependent degradation of CDK12 and CDK13, and inhibits serine 2 phosphorylation of RNA polymerase II (RNA polymerase II). YJ9069 triggers gene length-dependent transcription elongation defects, reduces the expression of DNA damage response genes, and induces DNA damage, cell cycle arrest and apoptosis. YJ9069 inhibits tumor growth in prostate cancer models. YJ9069 can be used for the research of prostate cancer, Ewing sarcoma and breast cancer.
-
PROTAC HPK1 Degrader-3
0 ImagesCat. No.: HY-162816Purity: 98.11%PROTAC HPK1 Degrader-3 is an orally active, PROTAC degrader that selectively targets HPK1, with a DC50 of 21.26 nM. PROTAC HPK1 Degrader-3 induces HPK1 degradation via the ubiquitin-proteasome system and forms a stable ternary complex with HPK1 and CRBN. It inhibits the SLP76 and NF-κB signaling pathways, enhances MAPK signal transduction, reverses the immunosuppressive factor-mediated inhibition of T cell cytokine secretion, and promotes the secretion of T cell immune cytokines. PROTAC HPK1 Degrader-3 suppresses tumor growth and enhances anti-PD-L1-mediated antitumor activity. It can be used in studies related to malignant tumors, such as colorectal cancer.
-
FPP29
0 ImagesCat. No.: HY-P11228Purity: 99.20%FPP29 is a potent peptide-based FOXM1 PROTAC degrader. FPP29 induces ubiquitination and degradation of FOXM1. FPP29 inhibits FOXM1 via the ubiquitin-proteasome degradation pathway. FPP29 induces Apoptosis. FPP29 suppresses tumor growth in hepatocellular carcinoma xenograft models. FPP29 can be used in the research of hepatocellular carcinoma (cell-penetrating peptide: (HY-P0133); VHL ligase ligand: (HY-P11493); linker: (HY-W013664); FOXM1 ligand: (HY-P11494)).
-
PROTAC PD-L1 degrader-2
0 ImagesCat. No.: HY-162972CAS No.: 2995357-09-8PROTAC PD-L1 degrader-2 is a PD-L1 PROTAC degrader with an IC50 of 197.4 nM and a Kd of 301 nM. PROTAC PD-L1 degrader-2 induces PD-L1 endocytosis, drives degradation via the proteasomal and lysosomal pathways, and inhibits the PD-1/PD-L1 interaction. As an immune activator, PROTAC PD-L1 degrader-2 increases the levels of CD4+, CD8+, granzyme B and perforin. PROTAC PD-L1 degrader-2 can be used in studies related to colon cancer immunology.
-
VHL-SNAP2-5C
0 ImagesCat. No.: HY-175417Purity: 99.98%VHL-SNAP2-5C is a PROTAC degrader targeting SNAP fusion proteins, with an IC50 of 0.33 μM for binding to VHL. VHL-SNAP2-5C covalently binds to the SNAP-tag target at one end and recruits the VHL ubiquitin E3 ligase at the other end to form a ternary complex, thereby inducing proteasome-dependent ubiquitination and degradation of SNAP fusion proteins through its heterobifunctional structure. VHL-SNAP2-5C can be used in studies of protein homeostasis and degradation mechanisms.
-
KT-474 hydrochloride
0 ImagesSynonyms: KYM-001 hydrochloride; PROTAC IRAK4 degrader-7 hydrochloride
-
SS47 TFA
0 ImagesCat. No.: HY-146231APurity: 99.88%SS47 TFA, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the in vivo antitumor efficacy of BCMA CAR-T cell research. HPK1, an immunosuppressive regulatory kinase, is a promising target for cancer immunotherapies. SS47 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
